Healthcare CTV, online video, and cross-channel planning

How to Audit a Pharma CTV Supply Chain

Audit pharma CTV supply from app identity and seller authorization through auction path, placement quality, fees, and outcomes.

Christian Guerrero Published 3 min read Part 8 of 10

The short answer

Start a CTV audit with what actually delivered: app or channel identity, seller, reseller path, device, placement, geography, and total fee stack. Reconcile that delivery with authorized seller records and contract expectations. A premium-sounding deal name is not evidence of premium supply.

Trace each impression path

Layer Evidence
App/channel Store ID, bundle, channel, content metadata
Publisher authorization app-ads.txt relationship
Seller identity sellers.json entry and seller type
Transaction Deal ID, auction type, floor, win price
Placement Instream status, screen, duration, pod position where available
Quality Invalid traffic, completion, audibility, suitability
Economics Media cost, platform/data/verification fees

IAB Tech Lab's app-ads.txt specification extends authorized seller declarations to apps, while sellers.json helps identify direct sellers and intermediaries. These transparency tools do not certify content quality or eliminate fraud (ads.txt/app-ads.txt; sellers.json).

Find duplicate and indirect paths

The same app inventory can arrive through several exchanges or resellers. Compare win rate, total cost, quality, and unique reach by path. Prefer a shorter route only when it preserves access and performance; fewer hops are not automatically better if a path adds legitimate value.

Validate the viewing environment

Confirm whether the impression was actually television-like, whether autoplay and sound behavior match expectations, and whether completion is meaningful. Investigate unknown apps, implausible volume, extreme completion patterns, repeated households, and delivery outside approved geography.

Connect quality to outcomes

Supply metrics diagnose whether an impression opportunity was credible. They do not prove business impact. Compare qualified reach and outcome evidence by supply tier, while accounting for audience and cost differences.

Hypothetical finding

A PMP supplies 40% of impressions but 65% of unique households, while a reseller-heavy path generates high completion and repeated frequency. The action may be to cap or remove that path, then monitor whether marginal reach improves. Percentages are illustrative.

Red flags that justify a deeper look

Some patterns in CTV delivery data should trigger an immediate investigation rather than waiting for the monthly audit:

  • Unknown or unnamed apps receiving meaningful spend.
  • Completion rates near 100% across a path, which can indicate non-human or forced viewing.
  • Delivery at unusual hours that does not match normal viewing patterns.
  • The same household IDs appearing at very high frequency from one path.
  • Sellers missing from app-ads.txt or listed with a different relationship type.
  • Sudden volume spikes from a new source after a bid or deal change.

None of these proves fraud on its own. Each is a reason to pull log-level data, check authorization, and ask the seller for an explanation. If the explanation is not satisfactory, pause the path while you investigate. Use the partner escalation framework for anything that looks material, and see how to use ads.txt, sellers.json, and SupplyChain objects together for the tracing steps.

Practical takeaway

CTV audits should end with an allow, monitor, or block decision at the most actionable supply level. The next step is a monthly path table joining seller transparency, placement, fees, household frequency, and outcome evidence.

Sources

External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.

Working through this decision on a real plan?

I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.